Denmark is cutting its forecast for 2025 economic growth by more than half following weaker prospects for pharmaceutical giant Novo Nordisk, according to documents seen by Bloomberg News https://t.co/hKhkMi2gmQ ...

NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the “Class Period”), of the important September 30, 2025 lead plaintiff deadline. SO WHAT: If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHA ...

EXTON, PA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- The recent approval of Novo Nordisk’s Wegovy (semaglutide 2.4mg) as the second treatment for metabolic dysfunction-associated steatohepatitis (MASH) represents a critical step forward in a condition with a vast patient population and significant unmet need. Highly anticipated by the field, this milestone is expected to transform the future of MASH care.  Findings from a Spherix Global Insights pulse study among gastroenterologists and hepatologists (n=77) conduct ...

Key Takeaways Novo Nordisk cut 2025 guidance as Wegovy and Ozempic face slower uptake and Eli Lilly rivalry.VKTX's VK2735 showed strong weight loss but raised safety and tolerability concerns in an ongoing study.Despite no marketed product, VKTX's valuation and cash position make it a safer relative bet.Novo Nordisk (NVO) and Viking Therapeutics (VKTX) have emerged as notable players in the obesity space.A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names Ozempic ...

诺和诺德，成立于 1923 年的丹麦制药巨头，最初专注于胰岛素和糖尿病治疗。1989 年，诺和诺德与 Novo Industri 合并，成为如今的诺和诺德集团。 根据纽约时报的报道，即使在今天，全球一半的胰岛素依然由诺和 诺德生产。 上世纪八十年代，科学家们发现，进食后人体会分泌一种名为「胰高血糖素样肽-1」（GLP-1）的激素。GLP- 1 能促进胰岛素分泌，带来饱腹感，从而抑制食欲。然而，人体内的 GLP-1 很快会被降解。而诺和诺德研发的 司美格鲁肽，能够模拟 GLP-1 的作用，并在体内长时间发挥效力，刺激胰岛素释放，降低血糖。 2017 年，司美格鲁肽以 Ozempic 的商品名在美国获批用于治疗 2 型糖尿病。随后，研究者又发现它具备显著 的减重效果。 2021 年，诺和诺德推出了减重版司美格鲁肽——Wegovy，并迅速走红。根据公司财报，2023 年 Wegovy 的销 量同比增长超过三倍，其中超过 9 成销售额来自美国。凭借 Ozempic 和 Wegovy 的巨大成功，诺和诺德一度成 为欧洲市值最高的公司，甚至超过了丹麦的 GDP。 ▲ Wegovy 注射笔 图源：Shelby Knowle ...

A competitor reported a successful late-stage clinical trial of a drug that could be very competitive with Wegovy.Novo Nordisk (NVO -1.90%) has risen to fame and prominence with its twin drugs Wegovy and Ozempic, with the former being particularly hot since it's approved for weight loss. However, on Tuesday a powerful rival to the company reported positive top-line results for a drug that could provide very stiff competition to the Danish pharmaceutical's top medication.Investors didn't react happily to thi ...

Company Overview - KabaFusion is a leading U.S. provider of essential chronic and acute infusion therapies, serving patients in 45 states through a nationwide network of home infusion pharmacies, ambulatory infusion sites, and home health agencies [2][5] - Founded in 2010 by Dr. Sohail Masood, KabaFusion focuses on patient-centered care and has over 30 years of clinical experience in infusion therapies [5] Investment and Growth - Novo Holdings has signed a definitive agreement to exit its investment in KabaFusion, which is subject to customary closing conditions [1] - Since partnering with Novo Holdings in November 2022, KabaFusion has significantly expanded its geographic footprint, enhanced its ambulatory infusion capabilities, and broadened its therapeutic offerings, nearly doubling in size [3][4] - The partnership with Novo Holdings has been instrumental in KabaFusion's growth trajectory and expansion initiatives, aiming to provide convenient and cost-effective therapy access to a broader array of patients [4] Future Directions - KabaFusion is entering a new chapter with a new partner, Nautic Partners, while continuing its commitment to delivering excellent patient care [4] - The company aims to maintain its patient-first mission and leverage its new partnership for further growth [4]

Key Takeaways Novo Nordisk cuts 2025 outlook, primarily due to weaker uptake of Wegovy in obesity markets.Alhemo wins EU approval for hemophilia A and B with inhibitors, adding to NVO's rare disease portfolio.Wegovy gains FDA nod for MASH, becoming the first GLP-1 therapy approved for liver disease treatment.Novo Nordisk (NVO) suffered a major setback in July after slashing its 2025 sales and profit outlook, triggering a decline in its share price. The downgrade reflects slower-than-expected momentum for it ...

"懂王"特朗普又撂下狠话了。 当地时间8月25日，特朗普表示，政府将大幅下调药品价格，幅度高达1400%至1500%，其重申对医药 价格的强硬立场，同时计划对进口药品加征更高关税。特朗普直言，"美国的药价要大动刀子。" 药品关税来袭，医药巨头瑟瑟发抖 理论上，一个产品的价格下跌幅度是不会超过100%，"懂王"特朗普虽然缺乏数学常识，但其意思倒也 非常明确的，这一消息犹如重磅炸弹，美国的药企巨头集体吓瘫，制药行业即将迎来史无前例的"地 震"。 事实上，特朗普此前曾向多家制药巨头企业发送了信函，其中包括礼来（LLY.US）、诺和诺德 （NVO.US）和辉瑞（PFE.US），敦促其在未来60天内采取措施降低美国药品价格。他威胁称，如果这 些公司拒绝配合，他将"动用一切手段保护美国家庭免受持续的药物定价滥用行为的侵害"。 另外，特朗普本月早些时候在接受采访时已经透露，计划对进口药品加征关税，最高或达250%，这是 迄今为止最严厉的方案。特朗普希望通过关税举措，促进医药制药商将制造业务带回美国。 对此，一些业内人士持反对意见，有分析指出，相关关税可能会推高成本，阻碍在美国的投资，扰乱药 品供应链，使患者面临风险。美国药 ...

| 排名 | 通用名 | 企业名称 | 2025年上半年销售额 | | --- | --- | --- | --- | | | | | (单位: 亿美元) | | 1 | 司美格鲁肽 | 诺和诺德 | 166. 83 | | 2 | 帕博利珠单抗 | 默沙东 | 151. 61 | | 3 | 替尔泊肽 | 礼来 | 147. 34 | | 4 | 阿哌沙班 | BMS/辉瑞 | 111. 71 | | 5 | 度普利尤单抗 | 赛诺菲/再生元 | 80. 15 | | 6 | 利生奇珠单抗 | 艾伯维 | 78. 48 | | 7 | 达雷妥尤单抗 | 張生 | 67. 76 | | 8 | 比克替拉韦+恩曲他演+ 富马酸丙酚替诺福韦 | 吉利德 | 66. 79 | | 9 | 恩格列净 | 勃林格殷格翰/礼来 | 64. 36 | | 10 | 艾乐卡夫特+替沙卡夫特+ 伊伐卡夫特 | 福泰制药 | 50. 87 | 随着跨国药企相继披露2025年半年报，今年上半年的全球畅销药TOP10也随之出炉。诺和诺德旗下黑马 司美格鲁肽继今年一季度反超"K药"（默沙东的帕博利珠单抗）后，今年上半年以1127.56 ...